Drug intelligence / Profile preview

zicronapine

Development stage: Phase 3
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Oral

Overview

Zicronapine (Lu 31-130) is an atypical antipsychotic small molecule that was under development by Lundbeck for the treatment of schizophrenia. It is characterized by a unique pharmacological profile, acting as a potent antagonist at dopamine D1, D2, and serotonin 5-HT2A receptors. Unlike most atypical antipsychotics which prioritize D2 and 5-HT2A antagonism, zicronapine possesses high affinity for the D1 receptor, a feature intended to improve cognitive and negative symptoms of schizophrenia while minimizing extrapyramidal side effects. Despite reaching Phase III clinical trials, Lundbeck announced the discontinuation of zicronapine's development in 2012, citing that the clinical data did not support a competitive profile compared to existing therapies.

Other names: zicronapine

Targets

DRD2 (Dopamine D2 Receptor)DRD1 (Dopamine D1 Receptor)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on zicronapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zicronapine.

Explore the full profile